Skip to main content
Journal cover image

Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction.

Publication ,  Journal Article
Gibson, CM; Kastelein, JJP; Phillips, AT; Aylward, PE; Yee, MK; Tendera, M; Nicholls, SJ; Pocock, S; Goodman, SG; Alexander, JH; Lincoff, AM ...
Published in: Am Heart J
January 2021

Acute myocardial infarction (MI) patients remain at high risk for recurrent events. Cholesterol efflux, mediated by apolipoprotein A-I, removes excess cholesterol from atherosclerotic plaque and transports it to the liver for excretion. Impaired cholesterol efflux is associated with higher cardiovascular (CV) event rates among both patients with stable coronary artery disease and recent MI. CSL112, a novel intravenous formulation of apolipoprotein A-I (human) derived from human plasma, increases cholesterol efflux capacity. AEGIS-II is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group trial investigating the efficacy and safety of CSL112 compared to placebo among high-risk acute MI participants. Eligibility criteria include age ≥ 18 years with type 1 (spontaneous) MI, evidence of multivessel stable coronary artery disease, and presence of diabetes requiring pharmacotherapy, or ≥2 of the following: age ≥ 65 years, prior MI, or peripheral artery disease. A target sample of 17,400 participants will be randomized 1:1 to receive 4 weekly infusions of CSL112 6 g or placebo, initiated prior to or on the day of discharge and within 5 days of first medical contact. The primary outcome is the time to first occurrence of the composite of CV death, MI, or stroke through 90 days. Key secondary outcomes include the total number of hospitalizations for coronary, cerebral, or peripheral ischemia through 90 days and time to first occurrence of the composite primary outcome through 180 and 365 days. AEGIS-II will be the first trial to formally test whether enhancing cholesterol efflux can reduce the rate of recurrent major adverse CV events.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

January 2021

Volume

231

Start / End Page

121 / 127

Location

United States

Related Subject Headings

  • Time Factors
  • Stroke
  • Randomized Controlled Trials as Topic
  • Plaque, Atherosclerotic
  • Placebos
  • Peripheral Vascular Diseases
  • Myocardial Ischemia
  • Myocardial Infarction
  • Multicenter Studies as Topic
  • Liver
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gibson, C. M., Kastelein, J. J. P., Phillips, A. T., Aylward, P. E., Yee, M. K., Tendera, M., … Mehran, R. (2021). Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction. Am Heart J, 231, 121–127. https://doi.org/10.1016/j.ahj.2020.10.052
Gibson, C Michael, John J. P. Kastelein, Adam T. Phillips, Philip E. Aylward, Megan K. Yee, Michal Tendera, Stephen J. Nicholls, et al. “Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction.Am Heart J 231 (January 2021): 121–27. https://doi.org/10.1016/j.ahj.2020.10.052.
Gibson CM, Kastelein JJP, Phillips AT, Aylward PE, Yee MK, Tendera M, Nicholls SJ, Pocock S, Goodman SG, Alexander JH, Lincoff AM, Bode C, Duffy D, Heise M, Berman G, Mears SJ, Tricoci P, Deckelbaum LI, Steg PG, Ridker P, Mehran R. Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction. Am Heart J. 2021 Jan;231:121–127.
Journal cover image

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

January 2021

Volume

231

Start / End Page

121 / 127

Location

United States

Related Subject Headings

  • Time Factors
  • Stroke
  • Randomized Controlled Trials as Topic
  • Plaque, Atherosclerotic
  • Placebos
  • Peripheral Vascular Diseases
  • Myocardial Ischemia
  • Myocardial Infarction
  • Multicenter Studies as Topic
  • Liver